We are thrilled to announce a strategic collaboration with AMD to accelerate the future of AI Drug Discovery. As part of the collaboration AMD will commit $20 Million to Absci -- strengthening Absci’s leadership in AI Drug Discovery and further expanding biopharma adoption of AMD Instinct Accelerators and ROCm software. "This partnership with AMD gives us the unique advantage of working closely with a partner that is deeply committed to supporting our needs while providing the most efficient, innovative AI solutions available.” - Sean McClain, Founder & CEO of Absci “We are proud to partner with Absci, a company at the forefront of AI-driven drug discovery, to help further accelerate breakthroughs in therapeutics and transform how biologic drugs are developed.” - Mark Papermaster, Executive Vice President and Chief Technology Officer of AMD. Read the full release here: https://lnkd.in/gqvtz7p3 #AI #Biologics #DrugDiscovery
Absci
Biotechnology Research
Vancouver, Washington 14,253 followers
Creating Drugs at the Speed of Ai
About us
Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to learn, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Our vision is to deliver breakthrough therapeutics at the click of a button, for everyone.
- Website
-
http://www.absci.com
External link for Absci
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Vancouver, Washington
- Type
- Public Company
- Founded
- 2011
- Specialties
- generative AI, synthetic biology, biologics, drug discovery, antibody development, artificial intelligence, pharmaceuticals, and biotechnology
Locations
-
Primary
Vancouver, Washington 98683, US
Employees at Absci
Updates
-
We are excited to welcome Michael Mangone as VP, Business Development! Help us give Mike a warm welcome with a like or a comment below!👇 #AI #Biologics #DrugDiscovery
-
-
Join Absci’s Head of Translational Research Amer-Denis Akkad's presentation at the Dermatology Innovation Forum 2025 in Orlando, Florida on March 6. Learn how we leveraged our generative AI platform to design ABS-201, a novel anti-prolactin receptor antibody for the potential treatment of androgenic alopecia, a disease that affects over 80M Americans. Our AI models engineered improved properties in vivo including: high-affinity and potency, extended half-life, and an excellent developability profile to create a potentially category-defining treatment for androgenic alopecia. Learn more here: https://lnkd.in/gy5Wvim4 #AI #Biologics #DrugDiscovery
-
-
Absci reposted this
You can hear in this short clip just how excited AMD is about the collaboration and investment in Absci. Together, we will tackle one of the hardest problems on earth—drug discovery—through the transformative power of generative AI and advanced computing. Absci is deploying AMD Instinct accelerators and ROCm software. By optimizing AI solutions, they will benefit from exceptional performance, reduced infrastructure costs, and faster innovation cycles. Watch the full discussion I have with Absci Founder and CEO Sean McClain to learn more. https://lnkd.in/gZCGGM4R
-
Are you a hands-on IT professional looking for your next challenge? Join Absci as our Head of IT and lead the design, development, and execution of our IT strategy. At Absci we’re using cutting-edge technology in generative AI and synthetic biology to develop new medicines. Join our mission to create better biologics for patients, faster! Learn more and apply here: https://lnkd.in/gNie-qk5 #Hiring #AI #IT #Biotech
-
-
In case you missed Absci Founder & CEO Sean McClain's talk at JPM, you can check out his fireside chat with AMD's CTO Mark Papermaster here: https://lnkd.in/gA5x3PY2 Our collaboration with AMD and exciting advancements on our platform and pipeline programs can be viewed here: https://lnkd.in/emtqW7tf #AI #Biologics #DrugDiscovery
AbSci & AMD Collaborate to Advance Biologics Design with Generative AI
-
Don't forget to watch Absci Founder & CEO Sean McClain's live JPM presentation tomorrow, including a virtual fireside chat with AMD's CTO Mark Papermaster, the latest on our pipeline assets, and platform advancements. Join us in person at the conference or online here: https://lnkd.in/emtqW7tf #AI #Biologics #DrugDiscovery
Absci Founder and CEO Sean McClain will be presenting at the 43rd annual JP Morgan Healthcare Conference on Wednesday, January 15th at 4:30 PM PT. Join us in person at the conference or online here: https://lnkd.in/emtqW7tf #AI #Biologics #DrugDiscovery
-
-
We are excited to announce we’ve formed a strategic partnership with Owkin to co-develop therapeutic candidates addressing novel targets in immuno-oncology and other indications, such as immunology and inflammation. Read the full release here: https://lnkd.in/gAQQnJ-T #AI #Biologics #DrugDiscovery
-
-
Absci reposted this
I’m thrilled to announce Absci’s strategic partnership with AMD, a collaboration that marks a significant milestone in the evolution of AI-powered drug discovery. AMD’s $20 million investment and our shared commitment to innovation will enable us to push the boundaries of what’s possible in designing biologics with AI. This partnership is not just about technology—it’s about the future of drug discovery and healthcare. By integrating AMD’s high-performance Instinct accelerators and ROCm software into our workflows, we are poised to accelerate the development of next-generation antibody therapeutics, ultimately aiming to get biologics to patients faster. I want to extend my heartfelt thanks to the incredible teams at both Absci and AMD who have worked tirelessly to make this partnership a reality - Lisa Su, Mark Papermaster, Mathew Hein, Sagi Paz, Patrick Rundell, Karim Bhalwani, Anush E., Aleks Shar, MBA 🇺🇦 🇺🇸, Harsh Menon, Ralph Wittig, Gagandeep Singh, Kristof Denolf, Brandi Martina, Amaro Taylor-Weiner, Zach Jonasson, Shelby Walker, James Mategko, Amir S., Todd Bedrick, Wen Sha, and Alexander Khan At Absci, we believe that bold ideas paired with the right technology can transform lives. This partnership is a testament to that belief, and we’re excited to lead the way in leveraging AI to redefine drug discovery. Here’s to the future of healthcare—and the breakthroughs yet to come 🚀 The Wall Street Journal
-
Read more about our new strategic collaboration with AMD in this article from The Wall Street Journal. "At Absci, we are always looking for ways to push the boundaries of what’s possible in drug discovery. AMD high-performance compute will enable us to further the development of next-generation antibody therapeutics, and we are excited about the potential that this partnership holds to accelerate the future of drug discovery. " - Sean McClain, Founder & CEO of Absci
AMD is investing $20 million in drug-discovery startup Absci, giving the AI chip supplier a toehold in the life-sciences market, a strategy it plans to replicate in other industries.
Exclusive | AMD Invests in Drug-Discovery Company Absci in Push to Sell AI Chips
wsj.com